Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 21;10(1):e003777. doi: 10.1136/jitc-2021-003777

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Enrollment and outcomes. *Twenty-one patients had no measurable disease by BICR at baseline (n=9) or had insufficient follow-up time (<6 months, n=12) and were excluded from this interim analysis efficacy-evaluable population; three patients with <6 months of follow-up time who had discontinued treatment (each with a best response of not evaluable) were included in the efficacy-evaluable population. ^†Sixteen patients had no measurable disease by BICR at baseline or had insufficient follow-up time (<6 months) and were excluded from this interim analysis efficacy-evaluable population. BICR, blinded independent central review; dMMR, mismatch repair deficient; EC, endometrial cancer; MMR, mismatch repair proficient; MMRun, mismatch repair unknown; MSI-H, microsatellite instability-high; MSS, microsatellite stable.